Noncommunicable diseases present African pharmaceutical industry with a $40bn opportunity

20th February 2017

By: Megan van Wyngaardt

Creamer Media Contributing Editor Online

     

Font size: - +

The growing incidence of noncommunicable diseases (NCDs) across sub-Saharan Africa, such as cardiovascular disease, cancer, diabetes and respiratory disease, in addition to infectious and parasitic illness, will present the pharmaceutical industry in Africa with a business opportunity of $40.8-billion in 2019, a new study shows.

However, owing to a heavy dependence on price, coupled with complexities associated with public sector tendering, it is difficult for multinationals to compete in this space, research firm Frost & Sullivan (F&S) has pointed out.

The private market, on the other hand, faces challenges with regard to fragmented payer channels between donors, private insurance payers and employers, even as high out-of-pocket expenses restrict patient access to medicines.

"An increase in health spending will encourage the local manufacture of drugs. We expect this increase in local formulation and filling to be protected by regulatory and tariff barriers, so international players will be looking for local contract manufacturers and other strategic partnerships,” said F&S transformational health research analyst Saravanan Thangaraj.

Further, investment was further driven by trends such as the improving regulatory environment in East Africa that is contributing to increasing regional harmonisation.

Pharmaceutical spending in Africa was also noted to be growing by 10.6%, with out-of-pocket spend on healthcare increasing, while the contribution of NCDs to the healthcare burden in Africa was set to rise by 21% through 2030.

The share of over-the-counter drugs in the region is also high, indicative of a culture of self-medication in Nigeria and Kenya.

“Addressing loopholes in the supply chain and distribution channels is crucial for foreign companies to ensure product availability and prevent circulation of counterfeit drugs.

“Investing in technical training of distributors and pharmacists, and product-specific initiatives like barcodes and holograms to track counterfeits, can also help minimise drug trafficking and enhance the brand’s image,” added Thangaraj.

Edited by Chanel de Bruyn
Creamer Media Senior Deputy Editor Online

Comments

The functionality you are trying to access is only available to subscribers.

If you are already a subscriber, you can Login Here.

If you are not a subscriber, you can subscribe now, by selecting one of the below options.

For more information or assistance, please contact us at subscriptions@creamermedia.co.za.

Option 1 (equivalent of R125 a month):

Receive a weekly copy of Creamer Media's Engineering News & Mining Weekly magazine
(print copy for those in South Africa and e-magazine for those outside of South Africa)
Receive daily email newsletters
Access to full search results
Access archive of magazine back copies
Access to Projects in Progress
Access to ONE Research Report of your choice in PDF format

Option 2 (equivalent of R375 a month):

All benefits from Option 1
PLUS
Access to Creamer Media's Research Channel Africa for ALL Research Reports, in PDF format, on various industrial and mining sectors including Electricity; Water; Energy Transition; Hydrogen; Roads, Rail and Ports; Coal; Gold; Platinum; Battery Metals; etc.

Already a subscriber?

Forgotten your password?

MAGAZINE & ONLINE

SUBSCRIBE

RESEARCH CHANNEL AFRICA

SUBSCRIBE

CORPORATE PACKAGES

CLICK FOR A QUOTATION